報價延遲最少15分鐘:2025/09/03 16:22 EDT
盤後時段
|
||||
|
3.69 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.72
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.79/-1.83
|
|
企業價值
143.32M
|
| 資產負債 |
|
每股賬面淨值
3.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.97M
|
|
每股收益
0.25
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/03 16:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. |
